A carregar...
Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
PURPOSE: Carfilzomib has been approved for use in relapsed and refractory multiple myeloma (RRMM). Cardiac toxicities have been reported with the use of carfilzomib. We aimed to determine the overall incidence and risk of cardiac toxicities in RRMM patients treated with carfilzomib using a meta-anal...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5985801/ https://ncbi.nlm.nih.gov/pubmed/29881259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S159818 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|